New Insight into the Effects of Heparinoids on Complement Inhibition by C1-inhibitor

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2016 Feb 15

PMID 26874675

Citations 14

Authors

F Poppelaars

J Damman

E L de Vrij

J G M Burgerhof

J Saye

M R Daha

H G Leuvenink

M E Uknis

M A J Seelen

Affiliations

Soon will be listed here.

Abstract

Complement activation is of major importance in numerous pathological conditions. Therefore, targeted complement inhibition is a promising therapeutic strategy. C1-esterase inhibitor (C1-INH) controls activation of the classical pathway (CP) and the lectin pathway (LP). However, conflicting data exist on inhibition of the alternative pathway (AP) by C1-INH. The inhibitory capacity of C1-INH for the CP is potentiated by heparin and other glycosaminoglycans, but no data exist for the LP and AP. The current study investigates the effects of C1-INH in the presence or absence of different clinically used heparinoids on the CP, LP and AP. Furthermore, the combined effects of heparinoids and C1-INH on coagulation were investigated. C1-INH, heparinoids or combinations were analysed in a dose-dependent fashion in the presence of pooled serum. Functional complement activities were measured simultaneously using the Wielisa(®) -kit. The activated partial thrombin time was determined using an automated coagulation analyser. The results showed that all three complement pathways were inhibited significantly by C1-INH or heparinoids. Next to their individual effects on complement activation, heparinoids also enhanced the inhibitory capacity of C1-INH significantly on the CP and LP. For the AP, significant potentiation of C1-INH by heparinoids was found; however, this was restricted to certain concentration ranges. At low concentrations the effect on blood coagulation by combining heparinoids with C1-INH was minimal. In conclusion, our study shows significant potentiating effects of heparinoids on the inhibition of all complement pathways by C1-INH. Therefore, their combined use is a promising and a potentially cost-effective treatment option for complement-mediated diseases.

Citing Articles

The Inhibition of Serine Proteases by Serpins Is Augmented by Negatively Charged Heparin: A Concise Review of Some Clinically Relevant Interactions.

Chan E, King P, Bai X, Schoffstall A, Sandhaus R, Buckle A Int J Mol Sci. 2024; 25(3).

PMID: 38339082 PMC: 10855260. DOI: 10.3390/ijms25031804.

Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.

Xing Z, Wang Y, Gong K, Chen Y BMC Nephrol. 2022; 23(1):232.

PMID: 35768780 PMC: 9245318. DOI: 10.1186/s12882-022-02829-0.

Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.

Bai X, Buckle A, Vladar E, Janoff E, Khare R, Ordway D Sci Rep. 2022; 12(1):5207.

PMID: 35338216 PMC: 8953970. DOI: 10.1038/s41598-022-09133-9.

Expression of a Crry/p65 is reduced in acute lung injury induced by extracellular histones.

Nagano F, Mizuno T, Imai M, Takahashi K, Tsuboi N, Maruyama S FEBS Open Bio. 2021; 12(1):192-202.

PMID: 34709768 PMC: 8727949. DOI: 10.1002/2211-5463.13322.

Skinner S, Derebail V, Poulton C, Bunch D, Roy-Chaudhury P, Key N Kidney Med. 2021; 3(4):607-618.

PMID: 34401728 PMC: 8350825. DOI: 10.1016/j.xkme.2021.04.006.

References

Damman J, Nijboer W, Schuurs T, Leuvenink H, Morariu A, Tullius S . Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant. 2010; 26(7):2345-54. DOI: 10.1093/ndt/gfq717. View

Keil L, Jimenez E, Guma M, Reyes M, Liguori C, Debari V . Biphasic response of complement to heparin: fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycle. Am J Hematol. 1995; 50(4):254-62. DOI: 10.1002/ajh.2830500406. View

Galebskaia L, Solovtsova I, Riumina E . [Modification of proteolytic complement cascade after treatment with exogenous heparin]. Vopr Med Khim. 2001; 47(1):91-7. View

Sacks S, Karegli J, Farrar C, Asgari E, Schwaeble W, Zhou W . Targeting complement at the time of transplantation. Adv Exp Med Biol. 2013; 735:247-55. DOI: 10.1007/978-1-4614-4118-2_17. View

Schreiber A, Kaplan A, Austen K . Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. 1973; 52(6):1402-9. PMC: 302404. DOI: 10.1172/JCI107313. View

Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M . Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010; 176(4):1648-59. PMC: 2843457. DOI: 10.2353/ajpath.2010.090276. View

Nielsen E, Waage C, Fure H, Brekke O, Sfyroera G, Lambris J . Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol. 2006; 44(8):1819-26. DOI: 10.1016/j.molimm.2006.10.003. View

Cugno M, Bos I, Lubbers Y, Hack C, AGOSTONI A . In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis. 2001; 12(4):253-60. DOI: 10.1097/00001721-200106000-00005. View

Damman J, Seelen M, Moers C, Daha M, Rahmel A, Leuvenink H . Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011; 92(2):163-9. DOI: 10.1097/TP.0b013e318222c9a0. View

10.

Zuraw B, Busse P, White M, Jacobs J, Lumry W, Baker J . Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010; 363(6):513-22. DOI: 10.1056/NEJMoa0805538. View

11.

Legendre C, Licht C, Muus P, Greenbaum L, Babu S, Bedrosian C . Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169-81. DOI: 10.1056/NEJMoa1208981. View

12.

McKay E, LAURELL A, Martensson U, Sjoholm A . Activation of Cl, the first component of complement, the generation of Clr-Cls and Cl- inactivator complexes in normal serum by heparin-affinity chromatography. Mol Immunol. 1981; 18(5):349-57. DOI: 10.1016/0161-5890(81)90095-x. View

13.

Brown K, Kondeatis E, Vaughan R, Kon S, Farmer C, Taylor J . Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med. 2006; 354(19):2014-23. DOI: 10.1056/NEJMoa052825. View

14.

Presanis J, Hajela K, Ambrus G, Gal P, Sim R . Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol. 2004; 40(13):921-9. DOI: 10.1016/j.molimm.2003.10.013. View

15.

Damman J, Hoeger S, Boneschansker L, Theruvath A, Waldherr R, Leuvenink H . Targeting complement activation in brain-dead donors improves renal function after transplantation. Transpl Immunol. 2011; 24(4):233-7. DOI: 10.1016/j.trim.2011.03.001. View

16.

Parej K, Dobo J, Zavodszky P, Gal P . The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. Mol Immunol. 2013; 54(3-4):415-22. DOI: 10.1016/j.molimm.2013.01.009. View

17.

Diaz J, Wrobleski S, Alvarado C, Hawley A, Doornbos N, Lester P . P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol. 2015; 35(4):829-37. PMC: 4489932. DOI: 10.1161/ATVBAHA.114.304457. View

18.

Seelen M, Roos A, Wieslander J, Mollnes T, Sjoholm A, Wurzner R . Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005; 296(1-2):187-98. DOI: 10.1016/j.jim.2004.11.016. View

19.

Maugeri N, de Gaetano G, Barbanti M, Donati M, Cerletti C . Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica. 2005; 90(6):833-9. View

20.

Pappalardo E, Zingale L, Terlizzi A, Zanichelli A, Folcioni A, Cicardi M . Mechanisms of C1-inhibitor deficiency. Immunobiology. 2002; 205(4-5):542-51. DOI: 10.1078/0171-2985-00153. View